Canal-U

Mon compte

Résultats de recherche

Nombre de programmes trouvés : 15175
Conférences

le (1h9m45s)

Cardiovascular Clinical Trialists (CVCT) Forum – Paris 2012 - Workshop 1 : How to secure the optimal dose(s) for phase III? (Michael GIBSON)

MODIGLIANI Workshop 1 - Friday November 30, 2012 :THE THROMBOSIS TRIALISTS WORKSHOPDOSE AND TARGET PATIENT POPULATIONS ISSUESChairpersons: Peter CLEMMENSEN, Copenhagen, DEN - George-Andrei DAN, Bucharest, ROMWebcast: Johanne SILVAIN, Paris, FRAThe development of new antithrombotic agents is a challenging area of cardiovascular medicine.These agents generally have a narrow therapeutic margin, and it is often difficult to find the optimal balance between efficacy (reduction of ischemic events) and safety (no excess of bleeding events).➢ Phase II trials are designed to generate signals of safety and efficacy and to select the dose or doses for phase III pivotal trials. However, phase II data ...
Voir la vidéo
Conférences

le (26m5s)

Cardiovascular Clinical Trialists (CVCT) Forum – Paris 2012 - Workshop 1 : Different doses, different indications? (Freek VERHEUGT)

MODIGLIANI Workshop 1 - Friday November 30, 2012 :THE THROMBOSIS TRIALISTS WORKSHOPDOSE AND TARGET PATIENT POPULATIONS ISSUESChairpersons: Peter CLEMMENSEN, Copenhagen, DEN - George-Andrei DAN, Bucharest, ROMWebcast: Johanne SILVAIN, Paris, FRAThe development of new antithrombotic agents is a challenging area of cardiovascular medicine.These agents generally have a narrow therapeutic margin, and it is often difficult to find the optimal balance between efficacy (reduction of ischemic events) and safety (no excess of bleeding events).➢ Phase II trials are designed to generate signals of safety and efficacy and to select the dose or doses for phase III pivotal trials. However, phase II data ...
Voir la vidéo
Conférences

le (13m7s)

Cardiovascular Clinical Trialists (CVCT) Forum – Paris 2012 - Workshop 1 : New indications: Is heart failure a viable new potential indication for anti-thrombosis therapy (Efthymios DELIARGYRIS)

MODIGLIANI Workshop 1 - Friday November 30, 2012 :THE THROMBOSIS TRIALISTS WORKSHOPDOSE AND TARGET PATIENT POPULATIONS ISSUESChairpersons: Peter CLEMMENSEN, Copenhagen, DEN - George-Andrei DAN, Bucharest, ROMWebcast: Johanne SILVAIN, Paris, FRAThe development of new antithrombotic agents is a challenging area of cardiovascular medicine.These agents generally have a narrow therapeutic margin, and it is often difficult to find the optimal balance between efficacy (reduction of ischemic events) and safety (no excess of bleeding events).➢ Phase II trials are designed to generate signals of safety and efficacy and to select the dose or doses for phase III pivotal trials. However, phase II data ...
Voir la vidéo
Conférences

le (52m37s)

Cardiovascular Clinical Trialists (CVCT) Forum – Paris 2012 - Workshop 1 : New indications: Is heart failure a viable new potential indication for anti-thrombosis therapy (Faiez ZANNAD)

MODIGLIANI Workshop 1 - Friday November 30, 2012 :THE THROMBOSIS TRIALISTS WORKSHOPDOSE AND TARGET PATIENT POPULATIONS ISSUESChairpersons: Peter CLEMMENSEN, Copenhagen, DEN - George-Andrei DAN, Bucharest, ROMWebcast: Johanne SILVAIN, Paris, FRAThe development of new antithrombotic agents is a challenging area of cardiovascular medicine.These agents generally have a narrow therapeutic margin, and it is often difficult to find the optimal balance between efficacy (reduction of ischemic events) and safety (no excess of bleeding events).➢ Phase II trials are designed to generate signals of safety and efficacy and to select the dose or doses for phase III pivotal trials. However, phase II data ...
Voir la vidéo
Conférences

le (9m33s)

Cardiovascular Clinical Trialists (CVCT) Forum – Paris 2012 - Workshop 1 : New indications: Is heart failure a viable new potential indication for anti-thrombosis therapy (Krishna PRASAD)

MODIGLIANI Workshop 1 - Friday November 30, 2012 :THE THROMBOSIS TRIALISTS WORKSHOPDOSE AND TARGET PATIENT POPULATIONS ISSUESChairpersons: Peter CLEMMENSEN, Copenhagen, DEN - George-Andrei DAN, Bucharest, ROMWebcast: Johanne SILVAIN, Paris, FRAThe development of new antithrombotic agents is a challenging area of cardiovascular medicine.These agents generally have a narrow therapeutic margin, and it is often difficult to find the optimal balance between efficacy (reduction of ischemic events) and safety (no excess of bleeding events).➢ Phase II trials are designed to generate signals of safety and efficacy and to select the dose or doses for phase III pivotal trials. However, phase II data ...
Voir la vidéo
Conférences

le (7m9s)

Cardiovascular Clinical Trialists (CVCT) Forum – Paris 2012 - Workshop 1 : Industry viewpoint (Joerg KOGLIN)

MODIGLIANI Workshop 1 - Friday November 30, 2012 :THE THROMBOSIS TRIALISTS WORKSHOPDOSE AND TARGET PATIENT POPULATIONS ISSUESChairpersons: Peter CLEMMENSEN, Copenhagen, DEN - George-Andrei DAN, Bucharest, ROMWebcast: Johanne SILVAIN, Paris, FRAThe development of new antithrombotic agents is a challenging area of cardiovascular medicine.These agents generally have a narrow therapeutic margin, and it is often difficult to find the optimal balance between efficacy (reduction of ischemic events) and safety (no excess of bleeding events).➢ Phase II trials are designed to generate signals of safety and efficacy and to select the dose or doses for phase III pivotal trials. However, phase II data ...
Voir la vidéo
Conférences

le (23m14s)

Cardiovascular Clinical Trialists (CVCT) Forum – Paris 2012 - Lunch Session 1 : Non randomized and/or non-blinded trials (Stuart POCOCK)

MODIGLIANI Lunch Debate Session 1 - Friday November 30, 2012THE DEVICE THERAPY TRIALISTS WORKSHOPChairpersons: Gaetano DE FERRARI, Pavia, ITA - Ileana PIÑA, New York, USAWebcast: Tariq AHMAD, Durham, USADevice trial methodology, regulatory and implementation issuesAdvances in interventional medical devices are increasingly affecting cardiovascular therapy, just as pharmacological innovation did the generation before. Yet, designing and conducting a device trial is challenging and drug trial designs may not necessarily be applied fully to device trials.➢ Although there is increasing recognition that this development process substantially differs from that for drugs, how much device trial methodology may deviate from drug trial methodology ...
Voir la vidéo
Label UNT Conférences

le (29m27s)

IP3S Lille 2012 : Problématique de l’interactivité d’un cours faisant appel à plusieurs disciplines ; résultats en odontologie et perspectives interdisciplinaires

Titre : IP3S Lille 2012 : Problématique de l’interactivité d’un cours faisant appel à plusieurs disciplines ; résultats en odontologie et perspectives interdisciplinairesAuteur (s) : Jean Claude ROBERT Université de Rennes 1, jean-claude.robert@univ-rennes1.fr Dominique DROZ Université de Nancy, d.droz@univ-lorraine.fr Emmanuelle NOIRRIT-ESCLASSAN Université de Toulouse, noirrit.e@gmail.com Corinne TARDIEU Université de Marseille, corinne.tardieu@univ-amu.fr Marine OLIVO Université de Rennes 1, marine.olivo@univ-rennes1.fr Résumé : Le cours d’odontologie pédiatrique sur le développement psychomoteur de l’enfant proposé au site de l’UNF3S avait pour objectif de présenter un panorama sur le développement psychomoteur de l’enfant selon la tranche d’âge.Nous voulions concevoir un cours à différents niveaux en privilégiant les médias pour ...
Voir la vidéo
Label UNT Conférences

le (27m40s)

IP3S Lille 2012 : Projet Métaciel : enseigner la prothèse autrement...

Titre : IP3S Lille 2012 : Projet Métaciel : enseigner la prothèse autrement...Auteur (s) : Marion BESSADET CHU Clermont-Ferrand, Service d’Odontologie, Hôtel-Dieu, F-63000 Clermont-Ferrand, France marion.bessadet@udamail.fr   Emmanuel NICOLAS Clermont Université, Université d’Auvergne, EA 4847, Centre de Recherche en Odontologie Clinique, BP 10448, F-63000 Clermont-Ferrand, emmanuel.nicolas@udamail.fr  FranceRésumé :Introduction :Les outils numériques pour l’éducation font partie des nouvelles pratiques qui peuvent faciliter l’apprentissage d’éléments techniques et/ou fondamentaux difficiles à appréhender. Dans ce cadre, l’apprentissage de la conception de la prothèse amovible partielle est toujours difficile. A ce titre, il a été développé sur le siteClermontois, un logiciel pédagogique « Métaciel » qui vise à faciliter l’apprentissage ...
Voir la vidéo
Label UNT Conférences

le (39m25s)

IP3S Lille 2012 : Formation hydride en Odontologie : un dispositif numérique novateur de formation.

Titre : IP3S Lille 2012 : Formation hydride en Odontologie : un dispositif numérique novateur de formation.Auteur (s) : Anne DAUTEL1,Justine LE CLERC2,Matthieu PERARD,Clémence CABASSE2,Marine OLIVO4,Anne LE GOFF1.1 - MCU-PH UFR Odontologie, Université de RENNES1 anne.dautel@univ-rennes1.fr anne.le-goff@univrennes1.fr2 AHU UFR Odontologie, Université de RENNES1 justine.leclerc@univ-rennes1.fr , clemence.cabasse@univ-rennes1.fr 3 - ex AHU UFR Odontologie, Université de RENNES1 matthieu.perard@univ-rennes1.fr4 - Ingénieur pédagogique, CIRM, Université RENNES1 marine.olivo@univ-rennes1.fr Résumé : Dans l’optique de la mise en place de la réforme LMD en santé, en 2009, la faculté d’Odontologie a décidé d’engager une refonte et un enrichissement de ses supports pédagogiques en mettant l’accent en ...
Voir la vidéo

 
FMSH
 
Facebook Twitter
Mon Compte